BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21540147)

  • 1. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
    Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
    Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
    Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
    Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
    Bonneau C; Paintaud G; Trédan O; Dubot C; Desvignes C; Dieras V; Taillibert S; Tresca P; Turbiez I; Li J; Passot C; Mefti F; Mouret-Fourme E; Le Rhun E; Gutierrez M
    Eur J Cancer; 2018 May; 95():75-84. PubMed ID: 29635147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.
    Zagouri F; Sergentanis TN; Bartsch R; Berghoff AS; Chrysikos D; de Azambuja E; Dimopoulos MA; Preusser M
    Breast Cancer Res Treat; 2013 May; 139(1):13-22. PubMed ID: 23588955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.
    Oberkampf F; Gutierrez M; Trabelsi Grati O; Le Rhun É; Trédan O; Turbiez I; Kadi A; Dubot C; Taillibert S; Vacher S; Bonneau C
    Neuro Oncol; 2023 Feb; 25(2):365-374. PubMed ID: 35868630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
    Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
    Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
    Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
    Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression.
    Zagouri F; Zoumpourlis P; Le Rhun E; Bartsch R; Zografos E; Apostolidou K; Dimopoulos MA; Preusser M
    Cancer Treat Rev; 2020 Aug; 88():102046. PubMed ID: 32599393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
    Martens J; Venuturumilli P; Corbets L; Bestul D
    Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.
    Perissinotti AJ; Reeves DJ
    Ann Pharmacother; 2010 Oct; 44(10):1633-40. PubMed ID: 20807868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
    Kumthekar PU; Avram MJ; Lassman AB; Lin NU; Lee E; Grimm SA; Schwartz M; Bell Burdett KL; Lukas RV; Dixit K; Perron I; Zhang H; Gradishar WJ; Pentsova EI; Jeyapalan S; Groves MD; Melisko M; Raizer JJ
    Neuro Oncol; 2023 Mar; 25(3):557-565. PubMed ID: 35948282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
    Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
    Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.
    García FJV; Carrión NP; de la Cruz-Merino L
    Medicine (Baltimore); 2020 Jan; 99(1):e18298. PubMed ID: 31895768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.
    Kingston B; Kayhanian H; Brooks C; Cox N; Chaabouni N; Redana S; Kalaitzaki E; Smith I; O'Brien M; Johnston S; Parton M; Noble J; Stanway S; Ring A; Turner N; Okines A
    Breast; 2017 Dec; 36():54-59. PubMed ID: 28968585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
    Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
    [No Abstract]   [Full Text] [Related]  

  • 19. Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.
    Maur M; Omarini C; Piacentini F; Fontana A; Pettorelli E; Cascinu S
    Am J Case Rep; 2017 Feb; 18():208-211. PubMed ID: 28242865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid].
    Gauchez AS; Pez E; Boutonnat J; Bourre JC; Pelletier L; Payan R; Mousseau M
    Ann Biol Clin (Paris); 2007; 65(6):653-8. PubMed ID: 18039611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.